Antibiotic innovation has dwindled to dangerously low levels in the past 30 years. Since resistance continues to evolve, this innovation deficit can have perilous consequences on patients. A number of new incentives have been suggested to stimulate greater antibacterial drug innovation. To design effective solutions, a greater understanding is needed of actual antibiotic discovery and development costs and timelines. Small and medium-sized enterprises (SMEs) undertake most discovery and early phase development for antibiotics and other drugs. This paper attempts to gather a better understanding of SMEs’ targets, costs, and durations related to discovery and early phase development of antibacterial therapies.
Kevin Outterson, Christine Ardal, Enrico Baraldi, Ursula Theuretzbacher, Francesco Ciabuschi, Jens Plahte & John-Arne Røttingen,
Insights into Early Stage of Antibiotic Development in Small and Medium-Sized Enterprises: A Survey of Targets, Costs, and Durations,
Journal of Pharmaceutical Policy and Practice
Available at: https://scholarship.law.bu.edu/faculty_scholarship/655